Journal article · 2014 · Open access
Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
AIDS Research and Therapy, 11(1), 33 · Published 1 January 2014 · DOI 10.1186/1742-6405-11-33
In brief
“Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial” is a 2014 journal article by Alain Lafeuillade and 5 co-authors, published in AIDS Research and Therapy. OpenAlex counts 34 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at AIDS Research and Therapy.
- Citations
- 34
- Most cited in
- 2016 (7)
- Field-weighted impact
- 1.75
- References
- 19
- Authors
- 6
Abstract
BACKGROUND: Ongoing HIV-1 replication in lymphoid cells is one explanation of the persistence of HIV-1 reservoirs despite highly active antiretroviral therapy (cART). We tested the potential of cART intensification by Maraviroc plus Raltegravir to decrease proviral HIV-1 DNA levels in lymphoid cells during a randomized trial. PATIENTS AND METHODS: We randomly assigned for 48 weeks 22 patients to continue their current first line regimen of Truvada® plus Kaletra® or intensify it with Maraviroc and Raltegravir. The primary objective was to obtain a 50% decrease in proviral HIV-1 DNA levels in lymphoid cells with intensification. Blood samples were drawn at W-2, W0, W2, W4, W12, W24 and W48. Plasma viremia, cellular proviral DNA and cellular RNA, 2-LTR circles and lymphocytes subsets were assayed using validated methods. Patients in the intensified group underwent a gut biopsy at baseline and W48 to measure proviral DNA levels. Statistical analysis used parametric and non-parametric tests. RESULTS: Ten patients in each arm completed the trial. The 2 populations were comparable at baseline. No change in the reservoir size was observed in the intensified arm compared to the control arm measured in peripheral blood mononuclear cells (PBMCs). No change in the reservoir size was observed in gut proviral DNA in the intensified arm. In this group, no increase in 2-LTR circles was observed as early as 2 weeks after intensification and no change was found in residual plasma RNA levels measured by the single copy assay. However, a decrease in CD8(+) T cells activation was observed at 24 and 48 weeks, as well as in PBMCs HIV-1 RNA levels. CONCLUSION: We conclude that the intensification of a Protease Inhibitor regimen with Maraviroc and Raltegravir does not impact the blood proviral DNA reservoir of HIV but can decrease the cell-associated HIV RNA, the CD8 activation and has a possible impact on rectal proviral HIV DNA in some patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier number NCT00935480.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Lafeuillade, A., Assi, A., Poggi, C., Cuquemelle, C., Jullian, E., & Tamalet, C. (2014). Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial. AIDS Research and Therapy, 11(1), 33. https://doi.org/10.1186/1742-6405-11-33
MLA 9
Lafeuillade, Alain, et al. “Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.” AIDS Research and Therapy, vol. 11, no. 1, 2014, p. 33. https://doi.org/10.1186/1742-6405-11-33.
Chicago
Lafeuillade, Alain, Assi Assi, Cécile Poggi, Caroline Cuquemelle, Eric Jullian, and Catherine Tamalet. 2014. “Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.” AIDS Research and Therapy 11 (1): 33. https://doi.org/10.1186/1742-6405-11-33.
Harvard
Lafeuillade, A. et al. (2014) ‘Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial’, AIDS Research and Therapy, 11(1), p. 33. doi:10.1186/1742-6405-11-33.
IEEE
A. Lafeuillade, A. Assi, C. Poggi, C. Cuquemelle, E. Jullian, and C. Tamalet, “Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial,” AIDS Research and Therapy, vol. 11, no. 1, p. 33, 2014, doi: 10.1186/1742-6405-11-33.
BibTeX
@article{lafeuillade2014failure,
title = {{Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial}},
author = {Lafeuillade, Alain and Assi, Assi and Poggi, Cécile and Cuquemelle, Caroline and Jullian, Eric and Tamalet, Catherine},
journal = {AIDS Research and Therapy},
year = {2014},
volume = {11},
number = {1},
pages = {33},
doi = {10.1186/1742-6405-11-33},
url = {https://doi.org/10.1186/1742-6405-11-33}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2016 | 7 | |
| 2017 | 4 | |
| 2018 | 4 | |
| 2019 | 2 | |
| 2020 | 3 | |
| 2021 | 2 | |
| 2022 | 2 | |
| 2023 | 3 | |
| 2024 | 1 | |
| 2025 | 2 |
Its field-weighted citation impact is 1.75: it has been cited 1.75 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- HIV-1 reservoir
- antiretroviral therapy intensification
- maraviroc
- raltegravir
- CCR5 antagonist
- integrase inhibitors
- lymphoid cells
- CD8+ T cell activation
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Lafeuillade, A., Assi, A., Poggi, C., Cuquemelle, C., Jullian, E., & Tamalet, C. (2014). Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial. AIDS Research and Therapy, 11(1), 33. https://doi.org/10.1186/1742-6405-11-33
How many times has this paper been cited?
34 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at AIDS Research and Therapy: sign in and open the PDF from this page.
Who wrote this paper?
Alain Lafeuillade, Assi Assi, Cécile Poggi, Caroline Cuquemelle, Eric Jullian, Catherine Tamalet.
What is the DOI of this paper?
10.1186/1742-6405-11-33, permanently at https://doi.org/10.1186/1742-6405-11-33. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.